RxDoctor Payments Data

Jose Sanchez, PA

Physician Assistant · la Feria, TXNPI 1497786107

Payments from drug & device makers

$3,095in general payments, 2019–2025

Across 254 payments — averaging $12.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$765
  • Lilly USA, LLC$320
  • Amgen$269
  • AbbVie$256
  • Novartis$228
  • Merck$181
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,99697%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,095 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$24,286
Medicare patients
55
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$173,481
JardianceEmpagliflozin84$118,840
FarxigaDapagliflozin Propanediol94$111,244
TrulicityDulaglutide45$87,751
KerendiaFinerenone32$56,549
MyrbetriqMirabegron43$43,026
JanuviaSitagliptin Phosphate26$33,128
EliquisApixaban24$30,207
SynjardyEmpagliflozin/Metformin Hcl16$23,420
VascepaIcosapent Ethyl26$23,338
ProliaDenosumab12$20,853
Synjardy XrEmpagliflozin/Metformin Hcl16$20,438
TradjentaLinagliptin21$20,141
MounjaroTirzepatide18$19,636
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta$43$182,840137 claims
Novo NordiskOzempic$765$173,481130 claims
AstraZenecaFarxiga, Breztri Aerosphere$168$123,015105 claims
Lilly USA, LLCTrulicity, Mounjaro$320$107,38763 claims
BayerKerendia$52$56,54932 claims
Astellas Pharma US IncMyrbetriq$161$43,02643 claims
MerckJanuvia$181$33,12826 claims
PfizerEliquis$40$30,20724 claims
AmgenProlia$269$20,85312 claims
GSKTrelegy Ellipta$17$19,05211 claims
AbbVieLinzess, Synthroid$256$16,74636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in la Feria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →